|4Feb 20, 5:15 PM ET

Buckbee Kevin K 4

4 · AbbVie Inc. · Filed Feb 20, 2024

Insider Transaction Report

Form 4
Period: 2024-02-15
Buckbee Kevin K
SVP, CONTROLLER
Transactions
  • Award

    Common Stock, $0.01 par value

    2024-02-15+7,08014,243 total
  • Award

    Common Stock, $0.01 par value

    2024-02-15+1,88816,131 total
  • Award

    Common Stock, $0.01 par value

    2024-02-15+1,47617,607 total
  • Award

    Common Stock, $0.01 par value

    2024-02-15+1,60419,211 total
  • Award

    Option (Right to buy)

    2024-02-15+6,9346,934 total
    Exercise: $0.00From: 2025-02-15Exp: 2034-02-14Common Stock (6,934 underlying)
Footnotes (5)
  • [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
  • [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
  • [F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
  • [F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
  • [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 2,312 on February 15, 2025, 2,311 on February 15, 2026, and 2,311 on February 15, 2027.

Documents

2 files